FBR Capital analyst, Vernon Bernardino, reiterated his Outperform rating as vaccine developer Novavax (NASDAQ: NVAX) reported 4Q15 financial results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE